19:29:36 Europe / Stockholm

Prenumeration

2024-02-28 10:08:00

Redeye reviews the case of Alzecure after the Q4 report, which offered no surprises, and continues to see an interesting neurology platform case with an exciting future. We adjust our base case somwhat due to external factors but reiterate our fundamental view.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/